Filtered By:
Source: NeLM - Cardiovascular Medicine
Management: National Institute for Health and Clinical Excelle
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 4 results found since Jan 2013.
NICE issues final appraisal determination on apixaban for prevention of stroke and systemic embolism in non-valvular atrial fibrillation
Source: NICE
Area: News
In its final appraisal determination (FAD), NICE has supported the use of apixaban as an option for preventing stroke and systemic embolism within its marketing authorisation, that is, in people with nonvalvular atrial fibrillation with one or more risk factors (prior stroke or ischaemic attack, age 75 years or older, hypertension, diabetes mellitus or symptomatic heart failure).
The appeal period for this appraisal will close on 6 February 2013.
Source: NeLM - Cardiovascular Medicine - January 23, 2013 Category: Cardiology Source Type: news
NICE issues final guidance supporting the use of apixaban for prevention of stroke and systemic embolism in non-valvular atrial fibrillation (TA 275)
Source: NICE
Area: Evidence > Guidelines
NICE has issued final guidance (TA 275) supporting the use of apixaban as an option for preventing stroke and systemic embolism within its marketing authorisation, that is, in people with nonvalvular atrial fibrillation with 1 or more risk factors such as:
. prior stroke or transient ischaemic attack
. age 75 years or older
. hypertension
. diabetes mellitus
. symptomatic heart failure.
NICE notes that the decision about whether to start treatment with apixaban should be made after an informed discussion between the clinici...
Source: NeLM - Cardiovascular Medicine - February 27, 2013 Category: Cardiology Source Type: news
NICE costing statement for its guidance on apixaban for prevention of stroke and systemic embolism in non-valvular atrial fibrillation (TA 275)
Source: NICE
Area: News
NICE has published a costing statement to accompany its guidance on the use of apixaban for preventing stroke and systemic embolism in nonvalvular atrial fibrillation (TA 275).
The statement notes that "Apixaban provides an alternative treatment option at a comparable cost and therefore it is anticipated that there will not be a significant cost impact as a result of implementing this guidance."
Source: NeLM - Cardiovascular Medicine - February 27, 2013 Category: Cardiology Source Type: news
NHS Evidence expert commentary: Benefits of drug therapy are unclear for mild hypertension
Source: NHS Evidence
Area: News
The January edition of 'Eyes on Evidence', the free monthly e-bulletin from NHS Evidence covering major new published evidence as it emerges with an explanation about what it means for current practice, includes an expert commentary on new data from a Cochrane review that aimed to quantify the effects of antihypertensive drug therapy versus no treatment on mortality and morbidity in adults with mild hypertension and no evidence of cardiovascular disease. It included four RCTs with 8912 participants. The review concluded that, compared with placebo, antihypertensive treatment does not reduce...
Source: NeLM - Cardiovascular Medicine - January 10, 2013 Category: Cardiology Source Type: news